


Liposzómák előállítási módjai

Dr. Voszka István

- fejcsoportok
- nettó töltés nélkül (PC, PE)
- negatív (PS, PG)
- pozitív (gangliozid, mesterséges lipidek)
 - ↓
 - 10-30 % arányban
 - hidrofil molekulák bezárási hatásfoka nő
 - sejtekbe való felvétel hatásfoka nő
 - élettartam csökken



A felépítő lipidek


a) foszfolipidek

- a zsírsavlánc tulajdonságai befolyásolják a fázisátalakulást:
hosszabb zsírsavlánc – magasabb T_m

pl: DMPC (14:0) – 24 °C

DPPC (16:0) – 41,5 °C

DSPC (18:0) – 56 °C




Kettős kötés a zsírsavláncban – alacsonyabb T_m.


pl: DOPC (18:1) – -27 °C

Keverékek esetén a keverési aránytól
függő köztes érték: pl:


DPPC: DOPC (80:20) – -2 °C

DPPC: DOPC (70:30) – -7 °C






koleszterin (30-50 mol %)





destabilizál




stabilizál

Vizes fázis

- ozmolaritás változása – méretváltozás





- pH → 6,5 alatt ill. 8,5 felett destabilizál
- kétértékű kationok → aggregálódás, fúzió





Lipid – víz arány

CMC (critical micellar concentration)
CMT (critical micellar temperature)




BLM (bilayer lipid membrane, black lipid membrane)

- a transzport vizsgálatára



Liposzómák

- **MLV** (multilamellar vesicle)
- a kettősrétegek száma változik
- széles mérettartomány
- kis bezárási hatásfok



MLV

- előállítása a legegyszerűbb (lipidfilm készítés + vizes fázis hozzáadása)
 - fagyasztás (cseppfolyós N₂-ben
 - T~80 K) – felolvasztás (T_m fölé)
- Szürés: az átmérő és a rétegek száma csökkenhető







Figure 2. Rotary evaporator apparatus for evaporating off organic solvents. The figure shows the arrangement of rotary evaporator and water bath with a nitrogen bleed to control the vacuum. Drawing kindly provided by Dr F.J.Martin.



- **SUV** (small unilamellar vesicle)
(átmérő: 100 nm alatt, minimum 20-25 nm)
- kis bezárt térfogat
- állás során fúzióra hajlamos



- SUV előállítása:**
- MLV-ból ultrahangosztással










Fig. 4. Time course of sonication. Percent lecithin molecules in fraction II, Fig. 3, (O—O), percent N(CH₃)₂ groups giving high-resolution NMR integral (Δ—Δ), and absorbance at 300 nm (×—×) as a function of sonication time of a 1% (w/v) dispersion. The solid curve through the experimental points for percent molecules in fraction II and giving a high-resolution spectrum is calculated according to the theory of Finer *et al.* (1972) described in the text.



SUV előállítása:
- MLV-ből French press alkalmazásával



SUV előállítása:
gyors injektálással




- **LUV** (large unilamellar vesicle)

(átmérő 100 nm – 10 µm)

Előállítása:

- MLV-ból filtrációval
- SUV-ból fúzióval
- lassú injektálással




Speciális liposzómák

a) Stabilizált („stealth”-S), sokáig keringő liposzómák

A felszínre kötött molekulák (pl. monoszialoganglioizid-GM1, polietilénglikol -PEG, glukuronid származékok) elrejtik az immunrendszer elől.

- Telítetlen ill. töltött fejcsöportú lipidek beépítése a liposzómába csökkenti a cirkulációs időt.



LUV előállítása:

- fordított fázisú párologtatással











Fig. 3.16. A schematic presentation of REV method. Normally 20–60 µM of lipid are used, 3 ml of diethylether, or 6 ml of diisopropylether or diisopropylether/chloroform 1:1 mixture, or Freon and 1 ml of aqueous phase with dissolved molecules to be encapsulated are used.

Célsejt-szenzitív vagy immunliposzómák – antitestek a liposzóma felszínén → specifikus kötődés a megfelelő antitest-receptort hordozó sejttel. A célsejthez való kötődés destabilizálja a membránt → kiürülés.





Termoszenzitív liposzómák

TABLE 2

Stabilities of a CDDP-encapsulated SUV and a CDDP-encapsulated LUV liposome ($DPPC/DSPC = 9/1$, w/w) when stored at $4^\circ C$ and room temperature (RT)

Liposome	Month	$4^\circ C$	RT
SUV	0	97.5 ^a	—
	1	91.8 ^b	9.2 ^b
LUV	0	98.2	—
	1.5	98.2	95.1
	3	98.2	99.9
	6	97.1	96.3

^a The latencies (%) of the liposomes were used as a measure for liposomal stability. ^b Remarkable coalescence was observed.




Fig. 5. Temperature-dependent release of CDDP from a CDDP encapsulated SUV liposome composed of DPPC/DSPC (9/1, w/w) and CDDP encapsulated LUV liposomes composed of DPPC/DSPC (9/1, 7/3, 5/5 and 0/10, w/w). The liposomes were diluted with saline by 10 times and incubated in a water bath maintained at constant temperatures for 15 min. The release rate was plotted against incubation temperature. (●), SUV, DPPC/DSPC = 9/1; (■), LUV, DPPC/DSPC = 9/1; (▲), LUV, DPPC/DSPC = 7/3; (▼), LUV, DPPC/DSPC = 5/5; (○), LUV, DPPC alone.

Termoszenzitív liposzómák




Figure 6. Incorporation of [³H]MTX in Lewis lung tumours of double-tumour (right and left leg) mice 4 h after tail-vein injection of liposome-encapsulated [³H]MTX. In the top experiment, only the right leg tumour was heated. In the bottom experiment, neither the right nor the left leg tumours were heated. (Modified with permission from Weinstein, J. N. et al., 1979. Liposomes and local hyperthermia: selective delivery of methotrexate to heated tumors. *Science*, **204**, 188–191. Copyright 1979 American Association for the Advancement of Science.)




Figure 2. Extravasation of liposomes at 42°C in the tumour interstitium. The tumour was maintained at 34°C for 1 h and then heated at 42°C for another hour. Relative interstitial amount is the amount of liposomes in the tumour interstitium normalized to an initial vascular compartment volume. (Modified from *International Journal of Radiation Oncology, Biology, Physics*, 36, M. M. Gaber, N. Z. Wu, K. Hsu, K. S. Chen, M. W. Dewhurst, D. Papaphilippou, Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks, pp. 1177–1187, Copyright 1996, with permission from Elsevier Science).




Figure 7. L1210 tumour growth in mouse feet after treatment with free or liposome-encapsulated MTX with or without heating to 42°C. Shams were given anaesthesia only. (Modified from Weinstein et al., 1980 with permission.)










Figure 3. CDDP concentrations in the brain. Broken line shows the detectable limit of CDDP. N.D. is below the minimum level of detectability. Brain CDDP levels were significantly higher only when the CDDP-liposome was used with hyperthermia, while CDDP levels in the brains of other groups were undetectable.







Mágneses liposzómák





Figure 4. Time courses of ADR concentrations in A: tumor; B: plasma; C: liver; D: lung; E: heart; F: kidney following intravenous administration of ADR preparations via different administration modalities in osteosarcoma-bearing hamsters. Hamsters were studied 7 days after inoculation of osteosarcoma (tumor size was approximately 10 mm in diameter). The dose of ADR was fixed at 5 mg/kg body weight. One day prior to the animal study, a magnet with a magnetic field strength of 0.4 tesla was implanted in tumors in the magnetic ADR liposome group with magnetic force and in the ADR solution group. A non-magnetic neodymium alloy was also implanted in tumors in the magnetic ADR liposome group without magnetic force. Each value represents the mean \pm SD of 4 trials.

Lipid mikroszférák

- lipid monolayer ($d = 200 - 300$ nm)
- lipofil molekulák zárhatók be
- vízben és zsírban is rosszul oldódó molekulák a lecitin rétegen tartózkodhatnak
- nem alkalmas hidrofil molekulák szállítására




Typical Components for LM

Soybean oil	50 ~ 200 mg
Egg yolk lecithin	12 ~ 18 mg
Glycerol	22 ~ 25 mg
Cosurfactant ^a	
NaOH	Adjusted to 5 ~ 7 of pH
Water for injection	Adjusted to 1 ml

^a Fatty acid such an oleic acid.

Lipid mikroszférák



Commercially Available LM for DDS

LM	Drug	Content	Company
Limethason	Dexamethasone palmitate	4.0 mg	Green Cross
Liple	Prostaglandin E ₁	10 µg	Green Cross
Palux	Prostaglandin E ₁	10 µg	Taisho
Lipfen	Flurbiprofen axetil	50 mg	Green Cross
Ropian	Flurbiprofen axetil	50 mg	Kaken

